Mycl1 was amplified in 37.5–66.7% of the control tumors, whereas it was only amplified in 6% of the Mycl1 transgenic tumors, clearly validating Mycl1 as a driver for SCLC development. This evidence concerns the gene MYCL and small cell lung carcinoma.